

Athens, 14.10.2024

Announcement of the Publication of the Prospectus under the trade name “Attica Bank S.A.”

The société anonyme banking company under the trade name “ATTICA BANK SOCIETE ANONYME BANKING COMPANY” (“**Attica Bank**” or the “**Issuer**”) announces that, as of 14.10.2024, makes available to investors the prospectus for (i) the offering to the public in the Hellenic Republic and the admission to trading on the Main Market of the Regulated Securities Market of the Athens Stock Exchange (“**ATHEX**”) of up to 359,469,360 new ordinary registered shares, with voting rights and a nominal value of €0.05 each (the “**New SCI Shares**”), which will be issued by Attica Bank in the context of the increase of its share capital by up to €17,973,468, with payment in cash, at an offering price of €1.87 per each New SCI Share and with pre-emptive rights in favor of existing shareholders, at a ratio of 677.4209451157461 New SCI Shares per every old share of Attica Bank, and (ii) the offering to the public of up to 359,469,360 warrants (“**Warrants**”) issued by Attica Bank, and following their exercise by their warrant holders, the admission to trading on the Main Market of the Regulated Securities Market of the ATHEX of up to 1,258,142,760 new ordinary registered shares with voting rights and a nominal value of €0.05 each (the “**Warrant Exercise Shares**”).

The Prospectus, consists of separate documents, namely (a) the registration document (the «**Registration Document**»), (b) the summary (the “**Summary**”), (c) the securities note, which relates to the offering to the Hellenic Republic and the admission to trading on the Main Market of the Regulated Securities Market of the ATHEX of the New SCI Shares (the “**SCI Securities Note**”), and (d) the securities note, which relates to the offering of the Warrants to the Hellenic Republic and the admission of the Warrant Exercise Shares to trading on the Main Market of the Regulated Securities Market of the ATHEX (the «**Warrant Securities Note**»), each of which was approved by the Board of Directors of the HCMC on 14.10.2024, and which documents in whole constitute the prospectus within the meaning of Article 6 and Article 10 of Regulation (EU) 2017/1129, which was drafted in English, and includes a translation of the Summary in Greek, in accordance with Regulation (EU) 2017/1129, Delegated Regulations (EU) 2019/979 and (EU) 2019/980, Articles 57-68 of Law 4706/2020, as currently in force, and Decision no. 1/892/13.10.2020 of the Hellenic Capital Market Commission (the “**Prospectus**”).

More information on the New SCI Shares and the process for investors to exercise their pre-emptive rights is set out in section 4. «INFORMATION CONCERNING THE SECURITIES TO BE OFFERED AND ADMITTED TO TRADING» and in section 5. «TERMS AND CONDITIONS» of the SCI Securities Note of the Prospectus.

More information on the Warrants and the Warrants Exercise Shares is set out in section 4. «INFORMATION CONCERNING THE SECURITIES TO BE OFFERED AND ADMITTED TO TRADING» and in section 5. «TERMS AND CONDITIONS» of the Warrants Securities Note of the Prospectus.

The timetable for the share capital increase, the issuance and exercise of Warrants, as well as the admission of the New SCI Shares and the Warrant Exercise Shares is set out as follows:

Date	Event
14 October 2024	Approval of Prospectus by the HCMC.
14 October 2024	Publication of the Prospectus on the websites of the Issuer, the HCMC and ATHEX.
14 October 2024	Publication of announcement regarding the availability of the Prospectus in the Daily Statistical Bulletin of the ATHEX and on the Issuer's website.
14 October 2024	ATHEX approval for the admission to trading of the shares resulting from the Reverse Split and notification on the Share Capital Reduction. ATHEX approval for the admission to trading of pre-emptive rights.
14 October 2024	Announcement regarding the Reverse Split and the Share Capital Reduction.
14 October 2024	Announcement on the date of detachment of the pre-emptive rights, the period of trading and exercise of pre-emptive rights and the procedure of trading and exercise of pre-emptive rights and the acquisition of Warrants.
15 October 2024	Last day of trading of the existing ordinary shares prior to the Reverse Split and with pre-emptive rights.
16 October 2024	Temporary cessation of trading of the existing ordinary shares prior to the Reverse Split and detachment of pre-emptive rights - adjustment of share price.
17 October 2024	Record date for the beneficiaries of the Reverse Split and of pre-emptive rights in the share capital increase.
18 October 2024	Crediting of existing ordinary shares resulting from the Reverse Split.
18 October 2024	Crediting of pre-emptive rights on the Securities Accounts of the beneficiaries.
21 October 2024	Commencement of trading of the existing ordinary shares resulting from the Reverse Split.
21 October 2024	Commencement of trading and exercise of pre-emptive rights.
21 October 2024	Commencement of offering period for the Warrants.
30 October 2024	Last day of trading of pre-emptive rights.
4 November 2024	Last day of exercise of pre-emptive rights.
4 November 2024	End of offering period for the Warrants.
5 November 2024	Allocation and disposal of any unsubscribed New SCI Shares and their respective Warrants.
6 November 2024	Announcement on the subscription of the share capital increase and the acquisition of Warrants.
8 November 2024	Certification of payment of the share capital increase and issuance of Warrants.
8 November 2024	Commencement of exercise period of the Warrants.
12 November 2024	ATHEX approval for the admission to trading of the New SCI Shares.*

12 November 2024	Announcement on the approval regarding admission to trading and the date of commencement of trading of the New SCI Shares.
13 November 2024	Commencement of trading of the New SCI Shares.
28 November 2024	Last day of the exercise period of the Warrants**.
29 November 2024	Board resolution for the issuance of the Warrant Exercise Shares corresponding to Warrants exercised during the exercise period and the adjustment of the capital-related article of the Articles of Association. Certification of payment of the Warrant Exercise Shares.
3 December 2024	ATHEX approval regarding admission to trading of the Warrant Exercise Shares.*
3 December 2024	Announcement on the approval for the admission to trading and the commencement date of trading of the Warrant Exercise Shares.
4 December 2024	Commencement of trading of the Warrant Exercise Shares.

**Subject to the competent ATHEX committee meeting on that date.*

***Assuming that the exercise period will not be extended by the Board.*

Investors should note that the above timetable is indicative and subject to change, in which case Attica Bank will duly and timely inform the investors via a public announcement. The admission of the New SCI Shares and the Warrant Exercise Shares to trading is subject to ATHEX approval which is given following the submission of the required supporting documentation and inspection thereof by the ATHEX.

The entire Prospectus, which includes the Registration Document, the SCI Securities Note, the Warrants Securities Note and the Summary, as each one of the above separate documents was approved by the Board of Directors of the Hellenic Capital Market Commission on 14.10.2024, will be available to investors, in accordance with article 21, par.2 of Regulation (EU) 2017/1129, as in force, in electronic form on the following websites:

- Attica Bank: <https://www.atticabank.gr/el/group/investors/#enimerotika-deltia>
- ATHEX: <http://www.helex.gr/el/web/guest/company-prospectus>

Furthermore, the full text of the Prospectus will be available free of charge to the investing community and in printed form, upon request, at Attica Bank's branch network.

For more information, investors may address their queries to the email info@atticabank.gr .

ATTICA BANK S.A.